Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q3 EPS of ($1.01), $0.14 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $350 thousand versus the consensus estimate of $123.5 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.